Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease - Mick Reedy, MD
MD, medical students, PhD (faculty, post-docs) graduate students, Researchers and Scientists, MDPhDs, DO, NPs, PAs, RN, APRN, Psychologists, Faculty and resident specialties including neurology (adult and pediatric neurology, neuropsychology), neurosurgery, neuroradiology, interventional neuroradiology, developmental pediatrics.
Upon completion of this activity, participants will be able to:
- Compare levodopa, dopamine agonists, & monoamine oxidase type B inhibitors on the management of motor symptoms & in side effect profile in those with early Parkinson disease.
- Compare different levodopa formulations influence on the management of motor symptoms & in side effect profile in those with early Parkinson disease.
- Compare different dopamine agonist formulations in side effect profile in those with early Parkinson disease.
- Compare the long-term risk of disabling dyskinesia between levodopa & dopamine agonists in those with early Parkinson disease.
- Compare the risk of impulse control disorders between levodopa, dopamine agonists, & monoamine oxidase type B inhibitors in those with early Parkinson disease.
It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation.
* Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on, patients.
The ACCME does not consider providers of clinical services directly to patients to be ineligible companies.
For this accredited continuing educational activity all relevant financial relationships have been mitigated and detailed disclosures are listed below:
|In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.|
Credit Designation Statements
American Medical Association
The University of Wisconsin–Madison ICEP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Education Units
The University of Wisconsin–Madison, as a member of the University Continuing Education Association (UCEA), authorizes this program for .1 continuing education units (CEUs) or 1 hour.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 University of Wisconsin–Madison Continuing Education Hours
- 1.00 Approved for AMA PRA Category 1 Credit™
QUESTIONS ABOUT REGISTRATION
The University of Wisconsin provides equal opportunities in employment and programming, including Title IX requirements. The University of Wisconsin fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us at email@example.com
Computer, tablet, or other mobile device with sound.
Free, current version of Edge, Firefox, Safari, or Chrome. Some older browsers and Internet Explorer could produce error messages or not display the content correctly.
Free, current version of Adobe Acrobat Reader or other .pdf reader.